Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg significantly improves weight-related quality of life (IWQOL-Lite-CT) and health-related quality of life (SF-36v2) compared to placebo in adults with overweight or obesity, independent of the magnitude of weight loss in some domains.
If you have obesity or overweight with related health issues, once-weekly semaglutide 2.4 mg, combined with lifestyle changes, significantly improves your quality of life, including physical function, mental health, and control over food cravings, compared to placebo. This benefit is sustained over time and is driven by fat loss rather than muscle loss.
All IWQOL-Lite-CT scores (Physical Function, Physical, Psychosocial, and Total Score) improved with semaglutide 2.4 mg significantly more than with placebo. Across the trials, changes in SF-36v2 scores were generally in favor of semaglutide versus placebo.
Why this rating
Based on multiple phase 3 STEP trials (STEP 1-5) with large sample sizes and rigorous design, though some QOL endpoints were exploratory or supportive secondary.
Source
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program
Patrick M. O’Neil et al. · Postgraduate Medicine · 2022
DOI 10.1080/00325481.2022.2150006
More from this paper
- Semaglutide 2.4 mg treatment leads to preferential loss of fat mass over lean body mass, which supports improvements in physical function and walking capacity.Good
- Semaglutide 2.4 mg significantly improves control of eating, including craving control and craving for savory, sustained up to week 104, compared to placebo.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →